Researchers receive $4M to study AI’s role in diagnosing CVD

A team of researchers from West Virginia and Arkansas are beginning a four-year project aimed at using AI to improve the treatment of cardiovascular disease and cut healthcare costs.

The group—which includes representatives from West Virginia University (WVU), West Virginia State University, three separate University of Arkansas campuses and more—has received $4 million in funding from the National Science Foundation to explore how AI can detect cardiovascular disease before symptoms start to surface.

A key focus of the study, according to a prepared statement from WVU, is to address various challenges associated with AI research, including “new privacy methods to protect an individual’s health data, establishing trust in AI results, improved efficiency in data analysis by AI systems and a study of the misinformation and health-related propaganda found on social media.”

“We see this challenge as a unique opportunity for a technology-driven transformation of the economy in West Virginia and Arkansas, with a real potential for important scientific discovery in both AI and smart health applications,” Partho Sengupta, MD, chief of cardiology and director of the Center for Cardiac Innovation at the WVU Heart and Vascular Institute, said in the statement.

The project will also involve high school students, who will be taught about AI and take part in various experiments that revolve around learning how to track your own health.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.